ENGN - enGene Holdings Inc. Common Stock

ENGN - enGene Holdings Inc. Common Stock

https://www.engene.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

enGene Posts 78% Expense Jump in Q3

Motley Fool • 3 days, 21 hours ago • score: 0.00

enGene ( NASDAQ:ENGN ) , a clinical-stage gene therapy company advancing treatments for bladder cancer, released its fiscal 2025 third-quarter earnings on Sept. 11, 2025. The period was highlighted by key clinical and regulatory milestones, including reaching the target enrollment for its pivotal ...

Best Momentum Stocks to Buy for February 19th

Zacks Commentary • 6 months, 3 weeks ago • score: 0.22

NVMI, FRSH and ENGN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 19, 2024.

New Strong Buy Stocks for February 19th

Zacks Commentary • 6 months, 3 weeks ago

GE, OPRT, ENGN, FRSH and NVMI have been added to the Zacks Rank #1 (Strong Buy) List on February 19, 2024.

This aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - enGene Holdings ( NASDAQ:ENGN ) , aTyr Pharma ( NASDAQ:ATYR )

Benzinga • 6 months, 4 weeks ago • score: -0.02

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

enGene Holdings Inc. ( ENGN ) Upgraded to Strong Buy: Here's Why

Zacks Commentary • 8 months, 3 weeks ago • score: 0.34

enGene Holdings Inc. (ENGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Here's Why enGene Holdings Inc. ( ENGN ) is Poised for a Turnaround After Losing -16.9% in 4 Weeks

Zacks Commentary • 9 months ago • score: 0.26

enGene Holdings Inc. (ENGN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

This TechnipFMC Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - TechnipFMC ( NYSE:FTI )

Benzinga • 9 months, 4 weeks ago • score: 0.44

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Citigroup analyst Atif Malik initiated coverage on Astera Labs, Inc.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

enGene Holdings Inc., through its subsidiary enGene, Inc., is a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. The company is headquartered in Saint-Laurent, Canada.

52W High

$11.00

52W Low

$2.76

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

-0.39

Valuation

As of 2025-04-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-6.01

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

1.17

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

13.63%

Institutions (25–75% balanced)

89.73%

Shares Outstanding

51,105,000

Float

18,852,200

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-04-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

-1.63

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.34%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.6586

Previous

0.6692

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025